Acurx Pharmaceuticals, Inc. (ACXP) earnings
ACXP earnings moved a median of -2.59% by the close. Quarterly and annual ACXP reports and results, each read against the price at its own news timestamp. Back to the ACXP overview →
32 measured ACXP earnings events.
Where these ACXP earnings landedvs 30 measured ACXP earnings reactions
| Middle 50% of ACXP earnings reactions | -5.80% to +1.32% |
|---|---|
| Median reaction (to close) | -2.59% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 ACXP earnings events with a measured close landed between -5.80% and +1.32%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update | Press release | -2.79% | -0.36% | |
| Form 10-Q Acurx Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -2.79% | -0.36% | |
| Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update | Press release | +0.69% | -6.21% | |
| Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update | Press release | -3.21% | -5.96% | |
| Form 10-Q Acurx Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -3.21% | -5.96% | |
| Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update | Press release | +1.33% | +3.96% | |
| Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update | Press release | -1.65% | -8.71% | |
| Form 10-K Acurx Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -1.65% | -8.71% | |
| Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update | Press release | -1.01% | +0.51% | |
| Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update | Press release | +3.99% | -5.32% | |
| Form 10-Q Acurx Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +3.99% | -5.32% | |
| Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update | Press release | +0.16% | +4.43% | |
| Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update | Press release | -5.95% | — | |
| Form 10-Q Acurx Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update | Press release | -1.56% | -4.43% | |
| Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update | Press release | -0.20% | -2.59% | |
| Form 10-Q Acurx Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -0.20% | -2.59% | |
| Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update | Press release | +0.68% | +1.90% | |
| Form 10-K Acurx Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +0.50% | -15.46% | |
| Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update | Press release | -3.70% | -3.70% | |
| Form 10-Q Acurx Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -3.70% | -3.70% | |
| Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 | Press release | +0.00% | +1.49% | |
| Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update | Press release | -4.74% | -10.90% | |
| Form 10-Q Acurx Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -4.74% | -10.90% | |
| Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update | Press release | +0.41% | +0.82% | |
| Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update | Press release | +0.47% | +5.14% | |
| Form 10-Q Acurx Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.47% | +5.14% | |
| Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update | Press release | — | +4.08% | |
| Form 10-K Acurx Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -1.12% | -3.00% | |
| Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update | Press release | -2.56% | -2.02% | |
| Form 10-Q Acurx Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -2.56% | -2.02% | |
| Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update | Press release | -1.01% | +3.54% |
Keep exploring
More ACXP: analyst actions → · SEC filings → · ACXP overview →